Journal
CANCER LETTERS
Volume 210, Issue 1, Pages 41-46Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2004.02.023
Keywords
colon cancer; heterotopic xenografts; LY293111; gemcitabine
Categories
Funding
- NCI NIH HHS [CA72712] Funding Source: Medline
Ask authors/readers for more resources
New adjuvant therapies are needed for the treatment of stage III colon cancer. The essential fatty acids, linoleic and arachidonic acid enhance tumorigenesis through the cyclooxygenase and lipoxygenase pathways. Leukotriene B-4 (LTB4) is a product of 5-lipoxygenase (5-LOX) which has tumor-promoting effects. The LTB4 receptor antagonist, LY293111 inhibited tumor growth and induced apoptosis in vitro. The effectiveness of LY293111, alone and in combination with gemcitabine was investigated in a heterotopic xenograft model in athymic mice using HT29 and LoVo human colonic cancer cells. The combined therapy markedly inhibited tumor growth and could warrant consideration as a new therapeutic option. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available